Global Myeloid Cells Targeting Therapeutics Market to 2035 - by Type of Molecule, Therapeutic Area, Route of Administration and Geography - ResearchAndMarkets.com

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

This report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the myeloid cells targeting therapeutics market.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, March 15, 2022
Information
Tags: 
Biotechnology, Genetics, Health, Molecule, Inflammation, Survival, Therapy, Myeloid-derived suppressor cell, Administration, Patient, Leukemia, Partnership, Monocyte, Intravenous therapy, Publication, Tumor microenvironment, B cell, Potyvirus, Escape Room, Attention, Myelocyte, Investor, Macrophage, USD, Neoplasm, Small molecule, Cell, Neutrophil, Granulocyte, Prevalence, Chemoradiotherapy, Route of administration, Anti-neutrophil cytoplasmic antibody, Immune system, Myelodysplastic syndrome, Type, ANCA, Tumor-associated macrophage, Pharmaceutical industry, Marketing, Vaccine, Geography
Geotags: 
EUROPE, NORTH AMERICA, ASIA
Summary
Key Points: 
  • This report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the myeloid cells targeting therapeutics market.
  • With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches.
  • Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity.
  • How is the current and future opportunity, related to myeloid cells targeting therapeutics, likely to be distributed across key market segments?


The "Myeloid Cells Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035" report has been added to ResearchAndMarkets.com's offering.

This report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the myeloid cells targeting therapeutics market. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

With over 19 million new cancer cases and 10 million deaths reported in the year 2020, the global cancer burden continues to increase rapidly. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas.

The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils, to sustain an immunosuppressive environment. Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. Targeting these cells help in modulating cancer-associated activities, including immune evasion. Therefore, myeloid therapies have gained significant attention as a potential adjunct to currently used therapies, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation to enhance therapeutic response. In addition, myeloid cell targeting therapies are being investigated for their potential in the treatment of various inflammatory disorders.

Presently, several medical researchers and industry stakeholders are engaged in the development of therapeutics targeting myeloid cells that harness the immune system in order to treat a number of solid tumors, leukemias and some rare conditions, including myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from the ongoing studies and completed trials suggest that targeting of myeloid cells results in the delayed progression of solid tumors, thereby increasing the survival rate of the patients. Given the encouraging results, the domain has attracted the attention of many private and public investors who have invested around USD 4.9 billion over the last few years. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the myeloid cells targeting therapeutics market is anticipated to grow at a commendable pace in the mid to long-term.

Key Questions Answered

  • Who are the leading players engaged in the development of myeloid cells targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for myeloid cell targeting therapeutics?
  • What is the focus of various publications related to therapeutics targeting myeloid cells?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • How is the current and future opportunity, related to myeloid cells targeting therapeutics, likely to be distributed across key market segments?

Companies Mentioned

  • 3SBio
  • Abcam
  • Abramson Cancer Center (University of Pennsylvania)
  • Acerta Pharma
  • Albert Einstein College of Medicine
  • Alexandria Venture Investments
  • Allen Discovery Center (Tufts University)
  • Amgen
  • Arcus Biosciences
  • Array BioPharma (acquired by Pfizer)
  • Astellas Pharma
  • AstraZeneca
  • Barzilai Medical Center
  • Beckman Research Institute (City of Hope)
  • BeiGene
  • Bioblast Pharma
  • BioCryst Pharmaceuticals
  • Birmingham Veterans Administration Medical Center
  • Bristol-Myers Squibb
  • BVF Partners
  • California Institute for Regenerative Medicine
  • Carisma Therapeutics
  • CARMA Cell Therapies (a subsidiary of MaxCyte)
  • Case Western Reserve University
  • CATO SMS
  • Cedars-Sinai Medical Center
  • Celgene (a subsidiary of Bristol Myers Squibb)
  • Cellics Therapeutics
  • ChemoCentryx
  • Chroma Therapeutics
  • Cincinnati Children's Hospital Medical Center
  • Cleveland Clinic Lerner College of Medicine (CCLCM)
  • Columbia University
  • Cowen
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Dompe
  • Duke University
  • East China Normal University (ECNU)
  • Eli Lilly
  • Emory University
  • Enlivex Therapeutics
  • Feinberg School of Medicine (Northwestern University)
  • Five Prime Therapeutics (acquired by Amgen)
  • Gardiner Institute
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Goldman Sachs
  • H.C. Wainwright
  • Hadassah Medical Organization
  • Hospital for Sick Children (SickKids)
  • Houston Methodist Hospital
  • Huazhong University of Science and Technology (HUST)
  • Icahn School of Medicine
  • Idera Pharmaceuticals
  • IDM Research Laboratory
  • ImCheck Therapeutics
  • Immune-Onc Therapeutics
  • Infinity Pharmaceuticals
  • Janssen
  • And Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/z4msti

Copyright: 
Copyright Business Wire 2022